Understanding of cytokines and targeted therapy in macrophage activation syndrome.


Journal

Seminars in arthritis and rheumatism
ISSN: 1532-866X
Titre abrégé: Semin Arthritis Rheum
Pays: United States
ID NLM: 1306053

Informations de publication

Date de publication:
02 2021
Historique:
received: 14 10 2020
revised: 01 12 2020
accepted: 21 12 2020
pubmed: 2 1 2021
medline: 30 9 2021
entrez: 1 1 2021
Statut: ppublish

Résumé

Macrophage activation syndrome (MAS) is a potentially life-threatening complication of systemic autoinflammatory/autoimmune diseases, generally systemic juvenile idiopathic arthritis and adult-onset Still's disease. It is characterized by an excessive proliferation of macrophages and T lymphocytes. Recent research revealed that cytokine storm with elevated pro-inflammatory cytokines, including IFN-γ, IL-18, and IL-6, may be central to the pathogenesis of MAS. Though the mainstream of MAS treatment remains corticosteroids and cyclosporine, targeted therapies with anti-cytokine biologics are reported to be promising for controlling systemic inflammation in MAS.

Identifiants

pubmed: 33385860
pii: S0049-0172(20)30315-2
doi: 10.1016/j.semarthrit.2020.12.007
pii:
doi:

Substances chimiques

Cytokines 0
Cyclosporine 83HN0GTJ6D

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

198-210

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no conflict of interest.

Auteurs

Shunli Tang (S)

Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Sheng Li (S)

Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Siting Zheng (S)

Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Yuwei Ding (Y)

Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Dingxian Zhu (D)

Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Chuanyin Sun (C)

Department of Rheumatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Yongxian Hu (Y)

Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Jianjun Qiao (J)

Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: qiaojianjun@zju.edu.cn.

Hong Fang (H)

Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: fanghongzy@zju.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH